Key Phase 2 trial of DS-8201, co-developed by AstraZeneca and Phase III, reaches the main research end
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today, AstraZeneca and Daiichi Sankyocompany(http://announced that the joint development of antibody conjugatedrug(http://(aDC) (fam-8201), in the treatment of HER2-positive metastatic breast cancer patients in the key phase 2trial(http://DS-8201 has the potential to be a new treatment for breast cancer patients who have received at least two pre-HER2 targeted therapiesAbout DS-8201
DS-8201 is an innovative ADC targeting HER2 that connects the all-humanized monoclonal antibody trastuzumab of the target HER2 receptor to a new type of topological isoenzyme 1 inhibitor via a quadpeptide jointThis ADC can connect more cytotoxins to antibodies, potentially having a better anti-tumor effectIn 2017, the ADC was awarded breakthrough therapy by the U.SFDA(http://for the treatment of HER2-positive, localized advanced or metastatic breast cancer patients In October, the FDA accepted and qualified for the dS-8201's Biological Products Licensing (BLA) The study study called DESTINY-Breast01 is a key Phase 2 clinical study in which 184 patients participated in the trial received an average of six pre-treatments, including ado-trastub emtansine (T-DM1), trastuzumab, pertuzumab, etc The results showed that patients treated with DS-8201 achieved an objective remission rate (ORR) of 60.9% and a disease control rate (DCR) of 97.3% The median remission time (DOR) in patients was 14.8 months and the median progression less (PFS) was 16.4 months
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
